HK1253737A1 - 在ctdna中具有pik3ca突变的预选患者中用pi3k抑制剂治疗癌症 - Google Patents

在ctdna中具有pik3ca突变的预选患者中用pi3k抑制剂治疗癌症 Download PDF

Info

Publication number
HK1253737A1
HK1253737A1 HK18112889.9A HK18112889A HK1253737A1 HK 1253737 A1 HK1253737 A1 HK 1253737A1 HK 18112889 A HK18112889 A HK 18112889A HK 1253737 A1 HK1253737 A1 HK 1253737A1
Authority
HK
Hong Kong
Prior art keywords
cancer
patient
ctdna
preselected
treatment
Prior art date
Application number
HK18112889.9A
Other languages
English (en)
Chinese (zh)
Inventor
Emmanuelle DI TOMASO
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1253737A1 publication Critical patent/HK1253737A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK18112889.9A 2015-12-03 2016-11-30 在ctdna中具有pik3ca突变的预选患者中用pi3k抑制剂治疗癌症 HK1253737A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562262620P 2015-12-03 2015-12-03
US62/262,620 2015-12-03

Publications (1)

Publication Number Publication Date
HK1253737A1 true HK1253737A1 (zh) 2019-06-28

Family

ID=57517943

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112889.9A HK1253737A1 (zh) 2015-12-03 2016-11-30 在ctdna中具有pik3ca突变的预选患者中用pi3k抑制剂治疗癌症

Country Status (13)

Country Link
US (2) US20180353515A1 (enExample)
EP (1) EP3383391A1 (enExample)
JP (1) JP2018535997A (enExample)
KR (1) KR20180084830A (enExample)
CN (1) CN108366998A (enExample)
AU (1) AU2016362683B2 (enExample)
CA (1) CA3006419A1 (enExample)
HK (1) HK1253737A1 (enExample)
IL (1) IL259716A (enExample)
MX (1) MX2018006777A (enExample)
RU (1) RU2018123524A (enExample)
TW (1) TW201722429A (enExample)
WO (1) WO2017093905A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210355545A1 (en) * 2018-10-15 2021-11-18 The Johns Hopkins University Methods and materials for assessing and treating cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005010145A2 (en) 2003-07-05 2005-02-03 The Johns Hopkins University Method and compositions for detection and enumeration of genetic variations
ES2537633T3 (es) 2004-03-02 2015-06-10 The Johns Hopkins University Mutaciones del gen de PIK3CA en cánceres humanos
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
TWI471134B (zh) 2007-09-12 2015-02-01 Genentech Inc 肌醇磷脂3-激酶抑制劑化合物及化療劑之組合及使用方法
CA2701292C (en) 2007-10-25 2015-03-24 Genentech, Inc. Process for making thienopyrimidine compounds
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
JP2013545756A (ja) * 2010-11-16 2013-12-26 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッド 投与および治療方法
MX2014011682A (es) * 2012-03-29 2015-01-22 Novartis Ag Diagnostico farmaceutico.
EP3842554B1 (en) * 2014-05-09 2022-12-14 Memorial Sloan Kettering Cancer Center Biomarkers for response to pi3k inhibitors

Also Published As

Publication number Publication date
CA3006419A1 (en) 2017-06-08
CN108366998A (zh) 2018-08-03
US20200138824A1 (en) 2020-05-07
AU2016362683A1 (en) 2018-05-31
RU2018123524A3 (enExample) 2020-04-02
JP2018535997A (ja) 2018-12-06
KR20180084830A (ko) 2018-07-25
US20180353515A1 (en) 2018-12-13
IL259716A (en) 2018-07-31
TW201722429A (zh) 2017-07-01
MX2018006777A (es) 2018-08-01
AU2016362683B2 (en) 2019-11-07
WO2017093905A1 (en) 2017-06-08
EP3383391A1 (en) 2018-10-10
RU2018123524A (ru) 2020-01-09

Similar Documents

Publication Publication Date Title
WO2015172085A3 (en) Biomarkers for response to pi3k inhibitors
EA201890512A1 (ru) Способы лечения пациентов со злокачественными опухолями с использованием ингибиторов фарнезилтрансферазы
CY1117655T1 (el) Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων
EA201691683A1 (ru) Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме
WO2017066136A3 (en) Antibody agents specific for human cd19 and uses thereof
PH12015502792A1 (en) Crystalline bromodomain inhibitors
CY1116728T1 (el) Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων
BR112017020973A2 (pt) método para tratar câncer em um paciente
WO2017093804A3 (en) Materials and methods for treatment of alpha-1 antitrypsin deficiency
EA201890428A1 (ru) Ингибиторы контрольных точек иммунного ответа для применения в лечении различных видов рака крови
EP4491224A3 (en) Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
WO2015191777A3 (en) Devices and methods for collecting and stabilizing biological samples
WO2013010136A3 (en) Inhibitors of bruton's tyrosine kinase
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
EA201792182A1 (ru) Композиции и способы для лечения анемии
HK1250752A1 (zh) 治疗骨髓增生性障碍的方法
WO2018031490A3 (en) Anti-ox40 binding proteins
BR112016030363A2 (pt) método para remoção de fluido de um filtro de sangue por meio do aumento do fluxo após a conclusão de uma sessão de tratamento de sangue e aparelho de tratamento para a realização do método
WO2018069871A3 (en) Anti-kras binding proteins
EP4279128A3 (en) Novel antibody binding to tfpi and composition comprising the same
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
EA202091446A1 (ru) Способы лечения хронических воспалительных заболеваний
HK1232145A1 (zh) 雙功能化合物和用於降低尿酸水平的用途
MX2015017058A (es) Combinaciones farmaceuticas de un inhibidor de pi3k y un agente de desestabilizacion de microtubulos.
HK1200723A1 (en) Pharmaceutical diagnostic